Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement ( EASI -75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance ( EASI -90) and 35% achieved significant
